Abstract
Purpose SARS-CoV-2 infects cells via the human Angiotensin-converting enzyme 2 (ACE2) protein. The genetic variation of ACE2 function and expression across populations is still poorly understood. This study aims at better understanding the genetic basis of COVID-19 outcomes by studying association between genetic variation in ACE2 and disease severity in the Iranian population.
Methods We analyzed two large Iranian cohorts and several publicly available human population variant databases to identify novel and previously known ACE2 exonic variants present in the Iranian population and considered those as candidate variants for association between genetic variation and disease severity. We genotyped these variants across three groups of COVID-19 patients with different clinical outcomes (mild disease, severe disease, and death) and evaluated this genetic variation with regard to clinical outcomes.
Results We identified 32 exonic variants present in Iranian cohorts or other public variant databases. Among those, 11 variants are novel and have thus not been described in other populations previously. Following genotyping of these 32 candidate variants, only the synonymous polymorphism (c.2247G>A) was detected across the three groups of COVID-19 patients.
Conclusion Genetic variability of known and novel exonic variants was low among our COVID-19 patients. Our results do not provide support for the hypothesis that exonic variation in ACE2 has a sizeable impact on COVID-19 severity across the Iranian population.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Work by A.A. and Y.M. was supported by Research Council KU Leuven: C14/18/092 SymBioSys3 CELSA-HIDUCTION CELSA/17/032. Flemish Government: IWT: Exaptation Ph.D. grants. FWO 06260 (Iterative and multi-level methods for Bayesian multirelational factorization with features) Elixir I002819N. This research received funding from the Flemish Government (AI Research Program). VLAIO PM: Augmenting Therapeutic Effectiveness through Novel Analytics. EU: "MELLODDY" This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831472. This Joint Undertaking receives support from the European Unions Horizon 2020 research and innovation programme and EFPIA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Baqiyatallah University of Medical Sciences ethics committee, approval ID: IR.BMSU.REC.1399.041.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
I confirm that all the data related to this study is available.
